Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Qol to Appoint Daiichi Sankyo Espha Chairman as Managing Director
March 15, 2012
- Nichi-Iko Announces New Med-Term Management Plan, Targets ¥130 Billion Sales in Mar 2016
March 15, 2012
- Baxter Reports Temporary Suspension in Shipments of Albumin Products to Japan
March 15, 2012
- MR Survey Shows Number of Doctors Visited, Detailing Activity Downtrend
March 14, 2012
- Pharmacists Rate Pfizer Highly for Generic Selection: Survey
March 14, 2012
- Nihon Chouzai to Provide Generic Drug Information System to Pharmacies of Other Companies
March 14, 2012
- Astellas and UMN Announce Favorable Phase II Results for Influenza HA Vaccine
March 14, 2012
- Sawai’s Next Midterm Management Plan Aims to Create a “Muscular Company”: Pres. Sawai
March 14, 2012
- MediciNova Obtains Notice of Patent Allowance for Ibudilast for Treatment of Chronic Neuropathic Pain
March 14, 2012
- Pfizer Reports 19% Boost in Sales in FY2011, “Continued Growth Possible” After Re-Pricing
March 13, 2012
- Upcoming Reforms “Ideal” for Promoting Use of Generic Drugs: President Sawai of Sawai Pharm.
March 13, 2012
- Nippon Shinyaku and Taiho to Cancel Licensing Agreement for Novel Antipruritic Agent
March 12, 2012
- UMN, IHI Start Construction of Biopharmaceutical Manufacturing Plant
March 12, 2012
- Novartis to Transfer Zaditen Ophthalmic Solution Marketing Rights to Alcon Japan
March 12, 2012
- Sosei Initiates PI Trial for Oropharyngeal Candidiasis Treatment SO-1105
March 12, 2012
- Taiyo to Discontinue Marketing Around 50 Products; Started Notifying Customers Last May
March 12, 2012
- Novo Nordisk Applies for Fixed-Dose Insulin Treatment
March 12, 2012
- Most Admired Pharma Companies in Japan
March 12, 2012
- Asahi Kasei to Acquire ZOLL Medical of the US for US$2.21 Bil.
March 12, 2012
- Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic While Patent Dispute Continues
March 12, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…